19 May 2017
: Case report
Casual or Causal? Two Unique Cases of Hodgkin’s Lymphoma: A Case Report and Literature Review
Challenging differential diagnosis, Unusual setting of medical care, Educational Purpose (only if useful for a systematic review or synthesis), Rare coexistence of disease or pathology
Faizan Malik1ABCEF*, Naveed Ali1E, Syed Imran Mustafa Jafri1E, Christian Fidler1EDOI: 10.12659/AJCR.903118
Am J Case Rep 2017; 18:553-557
Abstract
BACKGROUND: Immunosuppressive diseases and therapies have long been connected to risk of malignancies, especially lymphoma. With some diseases and drugs, the association is well established but the data is mostly anecdotal because of the rarity of the situation.
CASE REPORT: We present 2 rare cases. The first patient had psoriasis, was on etanercept, and developed Hodgkin’s lymphoma. This case is rare because psoriasis and etanercept do not usually cause lymphoma, and if they do, it is predominantly Epstein-Barr virus-positive non-Hodgkin’s lymphoma. The second patient had acquired immune deficiency syndrome (AIDS) and developed Hodgkin’s lymphoma while on highly active antiretroviral therapy (HAART). This case is rare because AIDS mostly causes Kaposi’s sarcoma or non-Hodgkin’s lymphoma due to immunosuppression, but whether it is AIDS or HAART therapy that leads to development of Hodgkin’s lymphoma in these patients is not clear.
CONCLUSIONS: Immunosuppression seems to be the primary culprit leading to lymphomas in these cases. The exact mechanism is still not completely understood.
Keywords: Hodgkin Disease, Lymphoma, AIDS-Related, Lymphoma, B-Cell, Psoriasis
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947545
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946515
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946523
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947489
Most Viewed Current Articles
21 Jun 2024 : Case report
98,085
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
52,814
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
33,151
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
23,669
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030